DLL3 and neoplasm: Tarlatamab is a TCE that directs the patient’s T cells to cancer cells expressing DLL3, independent of major histocompatibility complex (MHC) class I. The Tarlatamab mechanism of action is based on its ability to simultaneously bind to T cells via CD3 and to tumor cells via DLL3.